What You Should Know:
– Catalio Capital Management, LP (“Catalio”), a healthcare investment firm, today announced the successful close of its fourth venture fund, Catalio Nexus Fund IV (“Fund IV”), with over $400M in commitments across the Fund and its related co-investment vehicles.
– Launched in 2020 by Co-Founders George Petrocheilos and Dr. Jacob Vogelstein, Catalio currently manages $2B in assets across its private equity, private credit, and public equities strategies.
A Differentiated Investment Approach in Healthcare
Catalio’s core investment approach centers on identifying and supporting transformative healthcare companies that are spun out of leading academic institutions and led by repeat founders with deep scientific expertise. Their Nexus funds have invested in over 80 private companies since the firm’s inception five years ago. Catalio has also successfully sold or taken public a number of businesses over the years, consistently making distributions to its limited partners every year since its founding.
Fund IV’s Early Investments and Strategic Focus
To date, Fund IV has already made 16 investments, showcasing Catalio’s commitment to partnering with world-class teams and building category-defining life sciences businesses across all stages, from inception to IPO and beyond.
Recent highlights in Fund IV’s investment portfolio include:
- Cancer Diagnostics: Co-leading PinkDx’s $40 million Series A fundraise, focused on developing diagnostics for gynecological cancers.
- AI-Enabled Drug Discovery: Investing in the Series A financing of Superluminal Medicines, expanding Catalio’s portfolio in AI-enabled drug discovery.
- New Company Launches (Immunology & Inflammation): Launching Rhapsogen, co-founded by Catalio Venture Partner Dr. Jeffrey Ravetch at Rockefeller University, and TBD Pharma, co-founded by Catalio Venture Partner Dr. Bert Vogelstein at Johns Hopkins University.
- Late-Stage Investments: Participating in Imperative Care’s $150M Series E financing (a medical device company), a PIPE for Protara Therapeutics (an oncology company), and Alentis Therapeutics’ $180M Series D financing (a company developing antibody drug conjugates for oncology indications).
“We are grateful for the continued confidence and strong support we received for Fund IV from both new and existing high caliber investors,” said Olga Maltseva, Partner & Head of Operations at Catalio. “These new funds will allow Catalio to continue taking advantage of opportunities in a historic buyer’s market in biotech, and to keep distinguishing ourselves as a leading innovative healthcare investor around the globe.”
